MRK · News · 20261112N
Product / Drug Pipeline Progress
Merck & Co., Inc. · 2026-11-12 · Importance 34 · Surprise 42
Moderna reported positive Phase 3 results for intismeran autogene, an individualized cancer therapy developed with Merck. The report identifies the therapy as an oncology pipeline product but gives no trial efficacy details, launch timing, or commercial-market estimates. Moderna also described intismeran as part of its oncology expansion strategy.